| 证券代码 | GNLX.O |
| 证券名称 | Genelux Corp |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2023-01-26 |
| 首发价格(元) | 6 USD |
| 首发数量(股) | 2500000 |
| 首发募资额(元) | 15,000,000.00 USD |
| 首发主承销商 | The Benchmark Company, LLC |
| 货币单位 | USD |
| 公司名称 | Genelux Corporation |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 2625 Townsgate Road, Suite 230, Westlake Village, California, USA |
| 成立日期 | 2001-09 |
| 董事会主席 | Thomas Zindrick |
| 公司属地 | United States 美国 |
| 公司网址 | www.genelux.com |
| 电话 | +1 (805) 267-9889 |
| 传真 | - |
| 公司简介 | Genelux Corporation (“Genelux” or the “Company”), a Delaware Corporation, is a biomedical company located in Westlake Village, California. The Company is engaged in the research and development of diagnostic and therapeutic solutions for cancer for which there is no effective treatment today. The Company is focused on the development of therapeutic approaches for cancer that are designed to generate a personalized multi-prong attack to overwhelm a tumor’s sophisticated defense mechanisms. |